Spanish study reveals Real-World impact of COPD drug trixeo

NCT ID NCT06321731

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at the medical records of 718 adults with COPD in Spain who started taking the triple-combination inhaler Trixeo. Researchers wanted to see how many lung flare-ups (exacerbations) patients had in the year after starting the drug. The goal was to understand the real-world benefits and patient characteristics, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Show contact details

Locations

Research Site

Barcelona, Spain
Research Site

Granada, Spain
Research Site

Lleida, Spain
Research Site

Lugo, Spain
Research Site

Madrid, Spain
Research Site

Málaga, Spain
Research Site

Murcia, Spain
Research Site

Ourense, Spain
Research Site

Oviedo, Spain
Research Site

Palma de Mallorca, Spain
Research Site

Santa Cruz de Tenerife, Spain
Research Site

Seville, Spain
Research Site

Valencia, Spain
Research Site

Vitoria-Gasteiz, Spain
Research Site

Zaragoza, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.